Ritonavir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ritonavir: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Ritonavir is an HIV-1 protease inhibitor used as part of antiretroviral therapy (and as a pharmacokinetic booster in combination regimens); its own approved-indication and formulary records are not available in this evidence pack. The TxGNN model predicts a possible effect on feline acquired immunodeficiency syndrome (FIV) — a cat-only retroviral disease — but the only supporting clinical trial is a human HIV-1 study judged low relevance (Grade C, likely an ontology mismatch), and no supporting literature was found. This is a model-prediction-only signal with essentially no direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (antiretroviral protease inhibitor) — inferred from trial/mechanistic context; no formal indication record found in the local registry |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome (FIV) |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L4 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (original_moa is a data gap). Based on the contextual information present in this evidence pack, ritonavir is known as an HIV-1 aspartyl protease inhibitor that blocks viral particle maturation, and it is widely used in antiretroviral combination regimens (as reflected in the associated clinical trial, which studies ritonavir-boosted darunavir in HIV-1-infected patients).
The predicted new indication, FIV, is caused by a different lentivirus (feline immunodeficiency virus) that is only distantly related to HIV-1. While both are retroviruses of the same broad family, the structural homology between the FIV protease and the HIV-1 protease is limited, and cross-species inhibitory activity of ritonavir against FIV protease has not been demonstrated in this evidence pack.
The single retrieved clinical trial (NCT02770508) was explicitly graded Relevance C by the evidence pipeline, with the reasoning that it is a human HIV-1 trial mistakenly associated with this prediction (likely due to "AIDS" naming overlap between HIV/AIDS and feline "AIDS"), not a genuine FIV study. As such, the mechanistic rationale here is a same-drug-class analogy rather than direct evidence, and should be treated as hypothesis-generating only.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02770508 | Phase 4 | Completed | 145 | Compared ritonavir-boosted darunavir + lamivudine vs. ritonavir-boosted darunavir + tenofovir/emtricitabine (or lamivudine/tenofovir) in treatment-naïve human HIV-1 infected adults. Note: graded low relevance (Grade C) — this is a human HIV-1 study, not an FIV study; the association is likely a naming-based mismatch and does not constitute direct evidence for feline AIDS. |
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Ritonavir is not currently marketed in New Zealand (0 authorizations on file), so no product license information is available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (FIV) is a veterinary indication with only one associated clinical trial, and that trial is human-focused and graded as low/mismatched relevance — there is no genuine clinical or literature evidence linking ritonavir to FIV. Combined with missing MOA and safety/label data, the evidence base does not support proceeding at this time.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
- Genuine FIV-specific in vitro/in vivo protease-inhibition data (the current trial is not applicable)
- Re-validation of the disease-ontology mapping for this prediction to rule out a naming-based mismatch (human AIDS vs. feline AIDS)
- If pursuing the alternative rank-2 candidate (SIV infection), note it is also an animal-only indication with no human trial data — would require the same veterinary/translational evidence build-out
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.